Pretreatment of patients expecting bariatric surgery with the GLP-1- Analogon Liraglutid

niversitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 46 人开始时间: 2015年5月28日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Signed and dated informed consent obtained before any trial-related activities or procedures
•2.BMI of 35 – 50 kg/m²
•3.Fasting blood glucose > 140 mg / dL
•4.Diabetes mellitus type 2
•5.Oral antidiabetic treatment with Metformin and/or Sulfonylurea before and during the trial
•6.Scheduled for bariatric surgery

•1.Contraindication for liraglutide treatment as defined in the Summary of Product Characteristics (SmPC)
•2.Suspected or known hypersensitivity to liraglutide or any of its components
•3.Women of childbearing potential who are either breastfeeding, pregnant or not using a medically acceptable method of birth control
•4.Treatment with DPP IV inhibitors or GLP-1 analogues within the last three months
•5.Treatment with Insulin
•6.Pre-treatment with Liraglutide
•7.Type 1 diabetes mellitus
•8.HbA1c > 10 %
•9.Serious thyroid dysfunction (ft4 > 2 times normal value)
•10.Heart insufficiency (NYHA 3 – 4)
•11.Renal failure (GFR < 50 L/min)
•12.Suspected or known drug or alcohol abuse
•13.Participation in another clinical trial

发起方

niversitätsklinikum Hamburg-Eppendorf